{
  "id": 15610047,
  "title": "Adipositas: Sparen kann für den Staat teuer werden",
  "url": "https://urgent.news/2026/10/19/adipositas-sparen-kann-fur-den-staat-teuer-werden",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-19T12:04:31.000Z",
  "source": {
    "name": "Politico EU",
    "slug": "politico-eu",
    "url": "https://www.politico.eu/sponsored-content/adipositas-sparen-kann-fuer-den-staat-teuer-werden/"
  },
  "original_language": "de",
  "account": "German researchers estimate that obesity costs the country approximately 63 billion euros annually. Direct medical expenses account for about 29 billion euros, including doctor visits, treatments, and rehabilitation. Indirect costs, such as sick days, reduced productivity, and early retirement, add another 34 billion euros. Comparable figures are estimated by the Wifo Institute and the National Academy of Sciences Leopoldina, which even estimate the burden of overweight and obesity higher when considering additional costs. These studies, though using different methodologies, consistently show that the economic impact of the disease extends far beyond individual health insurance costs.\n\nObesity is not just a lifestyle issue; it's a chronic condition resulting from a complex interplay of biological, genetic, social, and environmental factors. Nearly one in five adults in Germany now suffer from obesity, up from 12% at the beginning of the 2000s. The Leopoldina refers to this as an \"obesity epidemic.\" The German health system primarily focuses on treating complications of obesity, such as type 2 diabetes or heart disease, rather than addressing obesity directly. This approach is relevant in the context of demographic changes and a shortage of healthcare professionals.\n\nA German Institute for Economic Research predicts that Germany could face a shortage of 4.3 million workers by 2036. Obesity, while not the sole cause, can affect workforce productivity. A responsible health policy should consider such connections when aiming to keep people healthy in the workforce. The English NHS has begun a phased rollout of medication-based treatments for adults with a body mass index of at least 35 kg/m2 and at least one accompanying condition. Treatment is provided through specialized services and is increasingly offered in general practitioner offices. This model sets a different political tone compared to Germany, which focuses heavily on the costs of modern medications and therapies. The key difference lies in considering not just the short-term costs of treatment, but also the costs of untreated or delayed treatment, potential savings from avoiding complications, fewer work absences, and a longer period in the workforce. The question for Germany is whether medication-based obesity treatment should remain excluded from the statutory health insurance or if it should adopt a targeted, phased access approach similar to England's, incorporating prevention, early detection, and guideline-based treatment.",
  "summary": "Adipositas wird in Deutschland vor allem als medizinisches oder individuelles Problem diskutiert. Doch die Erkrankung hat erhebliche wirtschaftliche Folgen. Der Blick ins Ausland zeigt, dass die politische Debatte über die Versorgung von Adipositas auch anders geführt werden kann.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}